These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30735612)

  • 1. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation.
    Dressler C; Eisert L; Pham PA; Nast A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1249-1260. PubMed ID: 30735612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
    Pham PA; Dressler C; Eisert L; Nast A; Werner RN
    Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New targets in psoriatic arthritis.
    Braun J
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
    Song GG; Lee YH
    Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials.
    Golicki D; Newada M; Lis J; Pol K; Hermanowski T; Tłustochowicz M
    Pol Arch Med Wewn; 2012; 122(1-2):22-32. PubMed ID: 22353705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for nail psoriasis.
    de Vries AC; Bogaards NA; Hooft L; Velema M; Pasch M; Lebwohl M; Spuls PI
    Cochrane Database Syst Rev; 2013 Jan; (1):CD007633. PubMed ID: 23440816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Song GG; Lee YH
    Clin Drug Investig; 2019 May; 39(5):421-428. PubMed ID: 30806969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for psoriatic arthritis.
    Jones G; Crotty M; Brooks P
    Cochrane Database Syst Rev; 2000; (3):CD000212. PubMed ID: 10908464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.